We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Import Alert on Two Apotex Facilities
FDA Issues Import Alert on Two Apotex Facilities
September 11, 2009
The FDA has placed all finished form drug products from two Apotex manufacturing facilities under an import alert following a warning letter earlier this year that cited serious good manufacturing practice (GMP) deficiencies at the company’s Etobicoke, Ontario, plant.